Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C

• Published in: Terapevtic̆eskii arhiv Vol. 84; no. 11; pp. 11 - 17
• Main Authors: Yushchuk, N D, Znoiko, O O, Balmasova, I P, Fedoseyeva, N V, Shmeleva, E V, Dudina, K R, Klimova, E A, Petrova, T V, Trofimov, D Yu, Belyi, P A, Safiullina, N Kh, Pypkina, E V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 01.01.2012
• Subjects: Adolescent; Adult; Antiviral Agents - therapeutic use; chronic hepatitis c; Female; Flow Cytometry; Genetic Testing; Genotype; hcv; hepatitis c virus; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - genetics; Hepatitis C, Chronic - immunology; Humans; il28b gene polymorphism; Immunogenetic Phenomena; Interferons; Interleukins - genetics; Killer Cells, Natural - immunology; Male; Middle Aged; natural killer cells; Polymorphism, Single Nucleotide; rapid virologic response; regulatory t cells; T-Lymphocytes, Regulatory - immunology; Time Factors; Treatment Outcome
• ISSN: 0040-3660; 2309-5342

To determine the correlation between interleukin 28B (IL28B) gene polymorphism in patients with chronic hepatitis C (CHC), the presence or absence a rapid virologic response to antiviral therapy, and a number of immunological characteristics as a basis for a personalized approach to treating the patients. Seventeen CHC patients infected with hepatitis C virus genotype 1b were examined and underwent genetic testing for IL28B gene polymorphism for rs12979860 (CC, CT or TT genotypes) and rs8099917 (TT, TG or GG genotypes) using the modified method of adjacent samples, which revealed single nucleotide substitutions in the genes. Their immunological parameters were identified by a flow cytometry technique by taking into account whether a rapid virologic response had been achieved. The key phenomena of a rapid virologic response in the representatives of different IL28B genotypes are the nonspecific proliferative activity of blood natural killer cells before treatment, as well as the count of regulatory T cells before and 4 weeks after therapy start. To predict the efficiency of antiviral therapy for CHC, it is desirable to supplement genetic studies with immunological data.